Block Admission Six Monthly Return

RNS Number : 2571X

Aptamer Group PLC

25 August 2022

 

25 August 2022

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Block Admission Six Monthly Return

Aptamer Group plc (AIM: APTA), the developer of novel Optimer ^®  binders to enable innovation in the life sciences industry, makes the following notification p ursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:

Name of Company	Aptamer Group plc
Name of Scheme	The Aptamer Group EMI Share Option Scheme
Period of Return (from/to)	25 February 2022 to 24 August 2022
Number and class of securities not issued at the start of the period under the scheme	2,063,200 Ordinary Shares
Number of securities issued under the scheme during the period	80,900
Options waived and not to be exercised	189,900
Balance under the scheme of securities not yet issued at the end of the period	1,792,400
Number and class of securities originally admitted and the date of admission	2,063,200 Ordinary Shares on 25 February 2022
Name of contact and telephone number	Jenny Cutler  [phone]

- ENDS -

For further information, please contact:

Aptamer Group plc	[phone]
Dr Arron Tolley - CEO
SPARK Advisory Partners Limited - Nominated Adviser	[phone]
Andrew Emmott / Adam Dawes
Liberum Capital Limited - Broker	[phone]
Richard Lindley / Ben Cryer / Will Hall / Cara Murphy
Consilium Strategic Communications	[phone]
Matthew Neal / Chris Welsh / Lucy Featherstone

[e-mail]

About Aptamer Group plc

Aptamer Group   develops custom affinity binders through its proprietary Optimer^® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145bn. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.

 

END

 

 

BLRBKPBNDBKDBFB